Novartis lifted its sales growth guidance for the mid-term after what it called a progress in delivering its pure-play strategy.
The Swiss pharmaceutical company upgraded on Tuesday its compound annual growth rate to 5% in the period between 2022 and 2027 and said that it expects a core operating income margin of around 40% by 2027.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8